ZHEJIANG GARDEN BIOPHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.41 CNY | +0.88% |
|
+3.54% | -3.39% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,809 | 5,872 | 8,639 | 7,813 | 7,929 | 6,486 |
| Enterprise Value (EV) 1 | 5,226 | 5,521 | 7,481 | 7,725 | 7,906 | 6,569 |
| P/E ratio | 18.9 x | 17.3 x | 29.4 x | 16.3 x | 20.6 x | 36.9 x |
| Yield | 1.07% | - | 0.65% | 1.31% | 0.97% | 0.6% |
| Capitalization / Revenue | 8.8 x | 8.17 x | 14 x | 6.99 x | 5.59 x | 5.92 x |
| EV / Revenue | 7.92 x | 7.69 x | 12.2 x | 6.92 x | 5.58 x | 6 x |
| EV / EBITDA | 14.3 x | 13.3 x | 25.6 x | 15.9 x | 17.3 x | 21.7 x |
| EV / FCF | -96.1 x | -27.2 x | -28.1 x | -18.3 x | -1,204 x | -21.6 x |
| FCF Yield | -1.04% | -3.67% | -3.56% | -5.45% | -0.08% | -4.62% |
| Price to Book | 3.72 x | 3.37 x | 2.97 x | 3.43 x | 3.13 x | 2.21 x |
| Nbr of stocks (in thousands) | 479,288 | 471,614 | 543,333 | 543,333 | 551,008 | 549,178 |
| Reference price 2 | 12.12 | 12.45 | 15.90 | 14.38 | 14.39 | 11.81 |
| Announcement Date | 3/25/19 | 2/27/20 | 4/16/21 | 3/29/22 | 3/27/23 | 4/15/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 660.2 | 718.4 | 614.9 | 1,117 | 1,418 | 1,095 |
| EBITDA 1 | 365.9 | 414.3 | 292 | 485.5 | 458.2 | 302.7 |
| EBIT 1 | 329.2 | 375.4 | 252.9 | 441.1 | 397.5 | 169.5 |
| Operating Margin | 49.87% | 52.26% | 41.13% | 39.49% | 28.04% | 15.49% |
| Earnings before Tax (EBT) 1 | 356.5 | 398.7 | 315 | 584.7 | 442.5 | 211 |
| Net income 1 | 307.4 | 343.7 | 272.3 | 479.8 | 383.7 | 192.3 |
| Net margin | 46.56% | 47.84% | 44.28% | 42.95% | 27.07% | 17.57% |
| EPS 2 | 0.6400 | 0.7200 | 0.5400 | 0.8800 | 0.7000 | 0.3200 |
| Free Cash Flow 1 | -54.36 | -202.6 | -266.1 | -421.1 | -6.568 | -303.7 |
| FCF margin | -8.23% | -28.2% | -43.28% | -37.69% | -0.46% | -27.75% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | 0.1300 | - | 0.1030 | 0.1880 | 0.1400 | 0.0710 |
| Announcement Date | 3/25/19 | 2/27/20 | 4/16/21 | 3/29/22 | 3/27/23 | 4/15/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 83.6 |
| Net Cash position 1 | 583 | 351 | 1,158 | 87.9 | 22.5 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 0.2762 x |
| Free Cash Flow 1 | -54.4 | -203 | -266 | -421 | -6.57 | -304 |
| ROE (net income / shareholders' equity) | 21.6% | 20.8% | 11.7% | 19.8% | 15.8% | 7.04% |
| ROA (Net income/ Total Assets) | 13.5% | 12.6% | 5.74% | 7.77% | 6.49% | 2.26% |
| Assets 1 | 2,272 | 2,729 | 4,741 | 6,174 | 5,917 | 8,526 |
| Book Value Per Share 2 | 3.260 | 3.700 | 5.360 | 4.190 | 4.590 | 5.340 |
| Cash Flow per Share 2 | 0.3900 | 1.070 | 2.130 | 0.9200 | 0.9900 | 2.770 |
| Capex 1 | 218 | 446 | 579 | 707 | 380 | 245 |
| Capex / Sales | 32.97% | 62.1% | 94.08% | 63.32% | 26.8% | 22.34% |
| Announcement Date | 3/25/19 | 2/27/20 | 4/16/21 | 3/29/22 | 3/27/23 | 4/15/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.39% | 851M | |
| +19.98% | 43.67B | |
| +20.67% | 22.51B | |
| +14.75% | 14.6B | |
| +14.32% | 13.74B | |
| +44.72% | 11.91B | |
| -8.37% | 7.04B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.42B |
- Stock Market
- Equities
- 300401 Stock
- Financials Zhejiang Garden Biopharmaceutical Co.,Ltd.
